Strategic

Eli Lilly acquires Calytrix Bio

Antibody therapies for rare blood diseases · USA

up to $1.5bnPurchase price according to the source

SourcingClub was not involved in this transaction.

The US pharmaceutical group Eli Lilly acquires the unlisted biotech company Calytrix Bio for up to $1.5bn. Calytrix was founded in 2025 and develops antibody therapies for rare blood diseases.

In context

The Deal-Radar lists 20 deals in Healthcare for November 2026, this is the 19th.

Deal-Radar editorial team · responsible:

Source from the same day: cash.ch , 16 Nov 2026

Who was involved.

Buyer
Eli Lilly
Target
Calytrix Bio
Type
Strategic
Country
USA
Source dated
16/11/2026
Purchase price
up to $1.5bn, according to the source

Deal-Radar no. 47-018 · publicly reported, no guarantee · SourcingClub was not involved in this transaction. Report an error · Sources and limits

We report publicly announced information and link the source; we accept no liability for its accuracy. No offer and no investment, legal or tax advice. The operators of linked pages are responsible for their content. We correct errors as soon as we learn of them. The context is based only on deals recorded in the Deal-Radar and is not complete.

November 2026 on the Deal-Radar.

79 of 190 deals so far are of the type Strategic.

  1. Strategic79
  2. Add-on32
  3. Carve-out23
  4. Funding round23
  5. Insolvency11
  6. Buy-out9
  7. Minority stake6
  8. Secondary5
  9. Merger1
  10. Succession1

New deals every day. By email on Mondays.

All deals of the previous week in one email, with source and adviser.

Weekly email every Monday, in German.

Information from public sources, without guarantee and without claim to completeness. No investment or legal advice. Published on 16 November 2026.